CA
LCTX icon

Corrado Advisors’s Lineage Cell Therapeutics LCTX Stock Holding History

Corrado Advisors’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-29,547
Closed -$61K – 99
2018
Q3 		$61K Sell
29,547
-15,344
-34% -$32.2K 0.04% 99
2018
Q2 		$80K Hold
44,891
– – 0.05% 105
2018
Q1 		$106K Sell
44,891
-40,691
-48% -$95.4K 0.06% 114
2017
Q4 		$161K Buy
85,582
+1,143
+1% +$2.5K 0.09% 110
2017
Q3 		$210K Buy
84,439
+13,716
+19% +$34K 0.12% 106
2017
Q2 		$195K Hold
70,723
– – 0.11% 105
2017
Q1 		$213K Buy
70,723
+32,090
+83% +$91.1K 0.12% 97
2016
Q4 		$122K Buy
38,633
+2,286
+6% +$7.02K 0.08% 102
2016
Q3 		$124K Buy
+36,347
New +$100K 0.08% 99

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
IA
IndexIQ Advisors New York $2.82B AUM 12.48% 1-Year Est. Return

Corrado Advisors's LCTX Position: Q4 2018 in Review

Corrado Advisors sold out of Lineage Cell Therapeutics (LCTX) in Q4 2018, closing a stake of 29,547 shares — an estimated $61K sold.

Corrado Advisors first reported a position in LCTX in Q3 2016 and held it in 9 quarters. The position peaked at $213K in Q1 2017. 105 funds tracked by Wall St. Rank hold LCTX as of Q4 2018.

  • Corrado Advisors reported no remaining Lineage Cell Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Corrado Advisors sold 29,547 Lineage Cell Therapeutics shares in Q4 2018, an estimated $61K.
  • Corrado Advisors first reported a position in Lineage Cell Therapeutics in Q3 2016 and held it in 9 quarters.
  • Corrado Advisors's Lineage Cell Therapeutics position peaked at $213K in Q1 2017.
  • 105 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2018.

Based on Corrado Advisors's 13F filing for Q4 2018, filed 9 Jan 2019.